Victoria Morken

Victoria Morken

Auto-generated profile, based on publicly available information

Victoria Morken

Northwestern University Feinberg School of Medicine, Chicago, IL, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
LPLaura M. Perry
Laura M. Perry
VMVictoria Morken
Victoria Morken
JPJohn Devin Peipert
John Devin Peipert
BYBetina Yanez
Betina Yanez
SGSofia F. Garcia
Sofia F. Garcia
DCDavid Cella
David Cella
Background: Patient-reported outcomes—symptoms, treatment side effects, and health-related quality of life—are important to consider in chronic illness care. The increasing availability of health IT to collect patient-reported outcomes and integrate results within the electronic health record provides an unprecedented opportunity to support patients’ symptom monitoring, shared decision-making, and effective use of the health care system. Objective: The objectives of this study are to co-design a dashboard that displays patient-reported outcomes along with other clinical data (eg, laboratory tests, medications, and appointments) within an electronic health record and conduct a longitudinal demonstration trial to evaluate whether the dashboard is associated with improved shared decision-making and disease management outcomes. Methods: Co-design teams comprising study investigators, patients with advanced cancer or chronic kidney disease, their care partners, and their clinicians will collaborate to develop the dashboard. Investigators will work with clinic staff to implement the co-designed dashboard for clinical testing during a demonstration trial. The primary outcome of the demonstration trial is whether the quality of shared decision-making increases from baseline to the 3-month follow-up. Secondary outcomes include longitudinal changes in satisfaction with care, self-efficacy in managing treatments and symptoms, health-related quality of life, and use of costly and potentially avoidable health care services. Implementation outcomes (ie, fidelity, appropriateness, acceptability, feasibility, reach, adoption, and sustainability) during the co-design process and demonstration trial will also be collected and summarized. Results: The dashboard co-design process was completed in May 2020, and data collection for the demonstration trial is anticipated to be completed by the end of July 2022. The results will be disseminated in at least one manuscript per study objective. Conclusions: This protocol combines stakeholder engagement, health care coproduction frameworks, and health IT to develop a clinically feasible model of person-centered care delivery. The results will inform our current understanding of how best to integrate patient-reported outcome measures into clinical workflows to improve outcomes and reduce the burden of chronic disease on patients and health care systems. International Registered Report Identifier (IRRID): DERR1-10.2196/38461

Verified
Journal Article
Open access
PDF file
VMVictoria Morken
Victoria Morken
LPLaura M. Perry
Laura M. Perry
ACAva Coughlin
Ava Coughlin
MOMary O’connor
Mary O’connor
RCRyan Chmiel
Ryan Chmiel
LHLisa Hirschhorn
Lisa Hirschhorn
Background: Shared decision making (SDM) is the process by which patients and clinicians exchange information and preferences to come to joint healthcare decisions. Clinical dashboards can support SDM by collecting, distilling, and presenting critical information, such as patient-reported outcomes (PROs), to be shared at points of care and in between appointments. We describe the implementation strategies and outcomes of a multistakeholder collaborative process known as “co-design” to develop a PRO-informed clinical dashboard to support SDM for patients with advanced cancer or chronic kidney disease (CKD). Methods: Across 14 sessions, two multidisciplinary teams comprising patients, care partners, clinicians, and other stakeholders iteratively co-designed an SDM dashboard for either advanced cancer (N = 25) or CKD (N = 24). Eligible patients, care partners, and frontline clinicians were identified by six physician champions. The co-design process included four key steps: (1) define “the problem”, (2) establish context of use, (3) build a consensus on design, and (4) define and test specifications. We also evaluated our success in implementing the co-design strategy using measures of fidelity, acceptability, adoption, feasibility, and effectiveness which were collected throughout the process. Results: Mean (M) scores across implementation measures of the co-design process were high, including observer-rated fidelity and adoption of co-design practices (M = 19.1 on a 7–21 scale, N = 36 ratings across 9 sessions), as well as acceptability based on the perceived degree of SDM that occurred during the co-design process (M = 10.4 on a 0 to 12 adapted collaboRATE scale). Capturing the feasibility and adoption of convening multistakeholder co-design teams, min–max normalized scores (ranging from 0 to 1) of stakeholder representation demonstrated that, on average, 95% of stakeholder types were represented for cancer sessions (M = 0.95) and 85% for CKD sessions (M = 0.85). The co-design process was rated as either “fully” or “partially” effective by 100% of respondents, in creating a dashboard that met its intended objective. Conclusions: A co-design process was successfully implemented to develop SDM clinical dashboards for advanced cancer and CKD care. We discuss key strategies and learnings from this process that may aid others in the development and uptake of patient-centered healthcare innovations.

21 December 2024 in JMIR Preprints
Verified
Preprint
Open access
SASaki Amagai
Saki Amagai
AHAlexandra Harris
Alexandra Harris
NMNisha Mohindra
Nisha Mohindra
SKSheetal Kircher
Sheetal Kircher
JLJeffrey A Linder
Jeffrey A Linder
NJNeil Jordan
Neil Jordan
BACKGROUND The US health care system faces escalating costs, increasing emphasis on patient autonomy, and a regulatory shift toward patient-centered care and patient-reported outcomes (PROs). Leveraging PROs to support shared decision-making has the potential to improve outcomes and reduce health care use for patients with advanced chronic conditions. OBJECTIVE This study aims to evaluate the impact of a PRO-based clinical dashboard on the use of costly health services among patients with advanced cancer and chronic kidney disease (CKD). METHODS We conducted a quasi-experimental, propensity score–weighted, difference-in-differences analysis using routinely collected data (June 2020 to January 2022) from a large US academic health system. Dashboard users were compared with contemporaneous nonexposed patients matched on clinical criteria. The primary outcomes were unplanned all-cause hospital admissions, potentially avoidable emergency department visits, excess days in acute care within 30 days of discharge, and 7-day readmissions. Cancer-specific secondary outcomes included acute encounters during outpatient chemotherapy, oncology triage use, advance directive completion, and hospice use. CKD-specific outcomes were CKD-related acute care use and disease progression. RESULTS In the advanced cancer cohort (dashboard users: n=284; dashboard nonusers: n=917), dashboard use was associated with significantly fewer chemotherapy-related emergency department or hospital encounters (ratio-in–odds ratios 0.35, 95% CI 0.16-0.75) and a nonsignificant 1.7–percentage point reduction in unplanned admissions (β=–0.017, 95% CI –0.107 to 0.072). Using Firth penalized logistic regression to reduce small sample bias, dashboard use was also associated with significantly higher odds of 7-day readmissions (ratio-in–odds ratios 8.58, 95% CI 2.28-32.32). Among readmissions in the dashboard user group, most (13/14, 93%) were scheduled by clinicians. Excess days in acute care increased by 4 percentage points (β=0.040, 95% CI –0.001 to 0.089). Advance directive completion declined significantly (β=–0.009, 95% CI –0.039 to 0.020). In the CKD cohort (dashboard users: n=365; dashboard nonusers: n=2137), no significant differences were observed for any primary or CKD-specific outcome. CONCLUSIONS In routine oncology practice, a PRO dashboard was associated with fewer acute care encounters during chemotherapy but more planned early readmissions. The dashboard had no measurable effect on patients with CKD. These disease-specific mixed results highlight the need to tailor dashboards to the clinical context and embed them within workflows that can act on real-time PRO information.

21 November 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SASaki Amagai
Saki Amagai
AHAlexandra Harris
Alexandra Harris
NMNisha Mohindra
Nisha Mohindra
SKSheetal Kircher
Sheetal Kircher
JLJeffrey A Linder
Jeffrey A Linder
NJNeil Jordan
Neil Jordan
Background: The US health care system faces escalating costs, increasing emphasis on patient autonomy, and a regulatory shift toward patient-centered care and patient-reported outcomes (PROs). Leveraging PROs to support shared decision-making has the potential to improve outcomes and reduce health care use for patients with advanced chronic conditions. Objective: This study aims to evaluate the impact of a PRO-based clinical dashboard on the use of costly health services among patients with advanced cancer and chronic kidney disease (CKD). Methods: We conducted a quasi-experimental, propensity score–weighted, difference-in-differences analysis using routinely collected data (June 2020 to January 2022) from a large US academic health system. Dashboard users were compared with contemporaneous nonexposed patients matched on clinical criteria. The primary outcomes were unplanned all-cause hospital admissions, potentially avoidable emergency department visits, excess days in acute care within 30 days of discharge, and 7-day readmissions. Cancer-specific secondary outcomes included acute encounters during outpatient chemotherapy, oncology triage use, advance directive completion, and hospice use. CKD-specific outcomes were CKD-related acute care use and disease progression. Results: In the advanced cancer cohort (dashboard users: n=284; dashboard nonusers: n=917), dashboard use was associated with significantly fewer chemotherapy-related emergency department or hospital encounters (ratio-in–odds ratios 0.35, 95% CI 0.16-0.75) and a nonsignificant 1.7–percentage point reduction in unplanned admissions (β=–0.017, 95% CI –0.107 to 0.072). Using Firth penalized logistic regression to reduce small sample bias, dashboard use was also associated with significantly higher odds of 7-day readmissions (ratio-in–odds ratios 8.58, 95% CI 2.28-32.32). Among readmissions in the dashboard user group, most (13/14, 93%) were scheduled by clinicians. Excess days in acute care increased by 4 percentage points (β=0.040, 95% CI –0.001 to 0.089). Advance directive completion declined significantly (β=–0.009, 95% CI –0.039 to 0.020). In the CKD cohort (dashboard users: n=365; dashboard nonusers: n=2137), no significant differences were observed for any primary or CKD-specific outcome. Conclusions: In routine oncology practice, a PRO dashboard was associated with fewer acute care encounters during chemotherapy but more planned early readmissions. The dashboard had no measurable effect on patients with CKD. These disease-specific mixed results highlight the need to tailor dashboards to the clinical context and embed them within workflows that can act on real-time PRO information.